By Dominic Chopping
STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio.
EQT co-led the funding round with Sanofi Ventures, while Roche Venture Fund and all existing investors also participated.
SpliceBio is developing therapies for genetic diseases using protein splicing technology.
Proceeds from the funding will support the company's phase 1/2 clinical development of SB-007, a therapy being developed to treat Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness.
Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areas.
Daniela Begolo, Managing Director at EQT Life Sciences, will join the SpliceBio board of directors.
Existing investors in SpliceBio include New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
June 11, 2025 04:10 ET (08:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.